Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes

Journal of Viral Hepatitis

Volumn 13, Issue 2, 2006, Pages 131-138

  Trepanier, J ^a   Tanner, J E ^a   Momparler, R L ^a   Le, O N L ^a   Alvarez, F ^a   Alfieri, C ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Antiviral; Core protein; Deoxyribozyme; DNAzyme; HCV

Indexed keywords

ANTIVIRUS AGENT; CORE PROTEIN; DEOXYRIBOZYME; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RNA CLEAVAGE; RNA SEQUENCE; VIRUS CORE; VIRUS GENOME;

BASE SEQUENCE; CELL LINE; DNA, CATALYTIC; HEPACIVIRUS; HUMANS; MOLECULAR SEQUENCE DATA; RNA, VIRAL; SUBSTRATE SPECIFICITY; VIRAL CORE PROTEINS;

EID: 33645100908     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00684.x     Document Type: Article

References (46)

1. Hoofnagle JH Course and outcome of hepatitis C Hepatology 2002 36 S21 S29
2. Shepherd J Waugh N Hewitson P Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review Health Technol Assess 2000 4 1 67
3. Sookoian SC New therapies on the horizon for hepatitis C Ann Hepatol 2003 2 164 170
4. Hugle T Cerny A Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C Rev Med Virol 2003 13 361 371
5. Zein NN Clinical significance of hepatitis C genotypes Clin Microbiol Rev 2000 13 223 235
6. Walker MP Appleby TC Zhong W Lau JY Hong Z Hepatitis C virus therapies: current treatments, targets and future perspectives Antivir Chem Chemother 2003 14 1 21
7. Oketani M Asahina Y Wu CH Wu GY Inhibition of hepatitis C virus-directed gene expression by a DNA ribonuclease J Hepatol 1999 31 628 634
8. Bartolome J Castillo I Carreno V Ribozymes as antiviral agents Minerva Med 2004 95 11 24
9. Shippy R Lockner R Farnsworth M Hampel A The hairpin ribozyme. Discovery, mechanism, and development for gene therapy Mol Biotechnol 1999 12 117 129
10. Opalinska JB Gewirtz AM Nucleic-acid therapeutics: basic principles and recent applications Nat Rev Drug Discov 2002 1 503 514
11. Kashani-Sabet M Ribozyme therapeutics J Investig Dermatol Symp Proc 2002 7 76 78
12. Steele D Kertsburg A Soukup GA Engineered catalytic RNA and DNA: new biochemical tools for drug discovery and design Am J Pharmacogenomics 2003 3 131 144
13. Goila R Banerjea AC Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: inhibition of the coreceptor function by DNA-enzyme FEBS Lett 1998 436 233 238
14. Kurreck J Bieber B Jahnel R Erdmann VA Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I J Biol Chem 2002 277 7099 7107
15. Santoro SW Joyce GF A general purpose RNA-cleaving DNA enzyme Proc Natl Acad Sci U S A 1997 94 4262 4266
16. Wu Y Yu L McMahon R Rossi JJ Forman SJ Snyder DS Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes) Hum Gene Ther 1999 10 2847 2857
17. Yen L Strittmatter SM Kalb RG Sequence-specific cleavage of Huntington mRNA by catalytic DNA Ann Neurol 1999 46 366 373
18. Chakraborti S Banerjea AC Inhibition of HIV-1 gene expression by novel DNA enzymes targeted to cleave HIV-1 TAR RNA: potential effectiveness against all HIV-1 isolates Mol Ther 2003 7 817 826
19. Goila R Banerjea AC Inhibition of hepatitis B virus X gene expression by novel DNA enzymes Biochem J 2001 353 701 708
20. Takahashi H Hamazaki H Habu Y et al. A new modified DNA enzyme that targets influenza virus A mRNA inhibits viral infection in cultured cells FEBS Lett 2004 560 69 74
21. Takamizawa A Mori C Fuke I et al. Structure and organization of the hepatitis C virus genome isolated from human carriers J Virol 1991 65 1105 1113
22. Mathews DH Sabina J Zuker M Turner DH Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure J Mol Biol 1999 288 911 940
23. Zuker M Mfold web server for nucleic acid folding and hybridization prediction Nucleic Acids Res 2003 31 3406 3415
24. Cairns MJ Hopkins TM Witherington C Sun LQ The influence of arm length asymmetry and base substitution on the activity of the 10-23 DNA enzyme Antisense Nucleic Acid Drug Dev 2000 10 323 332
25. Sambrook J Fritsch EF Maniatis T Mapping of RNA with ribonuclease and radiolabeled RNA probes In Nolan C ed Molecular Cloning: A Laboratory Manual 2nd edn Plainview Cold Spring Harbor Press 1989 7.71 7.78
26. Breslauer KJ Frank R Blocker H Marky LA Predicting DNA duplex stability from the base sequence Proc Natl Acad Sci U S A 1986 83 3746 3750
27. Rychlik W Spencer WJ Rhoads RE Optimization of the annealing temperature for DNA amplification in vitro Nucleic Acids Res 1990 18 6409 6412
28. Santoro SW Joyce GF Mechanism and utility of an RNA-cleaving DNA enzyme Biochemistry 1998 37 13330 13342
29. Zhang X Xu Y Ling H Hattori T Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme FEBS Lett 1999 458 151 156
30. Okamoto H Okada S Sugiyama Y et al. The 5′-terminal sequence of the hepatitis C virus genome Jpn J Exp Med 1990 60 167 177
31. Cairns MJ Hopkins TM Witherington C Wang L Sun LQ Target site selection for an RNA-cleaving catalytic DNA Nat Biotechnol 1999 17 480 486
32. Scherr M Rossi JJ Sczakiel G Patzel V RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts Nucleic Acids Res 2000 28 2455 2461
33. Sioud M Leirdal M Design of nuclease resistant protein kinase c alpha DNA enzymes with potential therapeutic application J Mol Biol 2000 296 937 947
34. Asahina Y Ito Y Wu CH Wu GY DNA ribonucleases that are active against intracellular hepatitis B viral RNA targets Hepatology 1998 28 547 554
35. Koff RS Hepatitis vaccines Infect Dis Clin North Am 2001 15 83 95
36. Ferenci P Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies J Antimicrob Chemother 2004 53 15 18
37. Locarnini SA Mechanisms of drug resistance and novel approaches to therapy for chronic hepatitis C J Gastroenterol Hepatol 2002 17 Suppl. 3 S351 S359
38. Smith RM Walton CM Wu CH Wu GY Secondary structure and hybridization accessibility of hepatitis C virus 3′-terminal sequences J Virol 2002 76 9563 9574
39. Richardson P Kren BT Steer CJ In vivo application of non-viral vectors to the liver J Drug Target 2002 10 123 131
40. Wattiaux R Jadot M Laurent N Dubois F Wattiaux-De Coninck S Cationic lipids delay the transfer of plasmid DNA to lysosomes Biochem Biophys Res Commun 1996 227 448 454
41. Stein CA Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism J Natl Cancer Inst 1996 88 391 393
42. Kurreck J Antisense technologies. Improvement through novel chemical modifications Eur J Biochem 2003 270 1628 1644
43. Juliano RL Yoo H Aspects of the transport and delivery of antisense oligonucleotides Curr Opin Mol Ther 2000 2 297 303
44. Khachigian LM Deoxyribozymes: cutting a path to a new class of therapeutics Curr Opin Mol Ther 2002 4 119 121
45. Santiago FS Lowe HC Kavurma MM et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury Nat Med 1999 5 1264 1269
46. Santiago FS Khachigian LM Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis J Mol Med 2002 79 695 706